ES2140418T3 - Flavivirus quimericos y/o flavivirus de crecimiento restringido. - Google Patents

Flavivirus quimericos y/o flavivirus de crecimiento restringido.

Info

Publication number
ES2140418T3
ES2140418T3 ES92920708T ES92920708T ES2140418T3 ES 2140418 T3 ES2140418 T3 ES 2140418T3 ES 92920708 T ES92920708 T ES 92920708T ES 92920708 T ES92920708 T ES 92920708T ES 2140418 T3 ES2140418 T3 ES 2140418T3
Authority
ES
Spain
Prior art keywords
flavivirus
chemical
viruses
virus
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92920708T
Other languages
English (en)
Inventor
Ching-Juh Lai
Michael Bray
Alexander G Pletnev
Ruhe Men
Robert M Chanock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2140418T3 publication Critical patent/ES2140418T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION INCLUYE UN VIRUS QUIMERICO PARA USO EN UNA PREPARACION DE VACUNAS QUE TIENEN UN GENOMA COMPRENDIENDO SECUENCIAS DE ACIDO NUCLEICO, CODIFICANDO AL MENOS UNA PROTEINA ESTRUCTURAL PROCEDENTE DE UN FLAVIVIRUS, Y SECUENCIAS DE ACIDO NUCLEICO CODIFICANDO PROTEINA NO ESTRUCTURAL PROCEDENTE DE OTRO FLAVIVIRUS. EL GENOMA INCLUYE PREFERENTEMENTE MUTACIONES DENTRO DEL GENOMA VIRAL QUE REDUCE LA VIRULENCIA DEL VIRUS Y, EN VERSION PARTICULARMENTE PREFERENTE, ESTAS VACUNAS SE DIRIGEN A FLAVIVIRUS TALES COMO VIRUS DE LA DENGUE (GRIPE), VIRUS DE LA ENCEFALITIS PORTADORA DE GARRAPATAS Y VIRUS DE LA ENCEFALITIS JAPONESA.
ES92920708T 1991-09-19 1992-09-18 Flavivirus quimericos y/o flavivirus de crecimiento restringido. Expired - Lifetime ES2140418T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76122491A 1991-09-19 1991-09-19
US76122291A 1991-09-19 1991-09-19

Publications (1)

Publication Number Publication Date
ES2140418T3 true ES2140418T3 (es) 2000-03-01

Family

ID=27116947

Family Applications (3)

Application Number Title Priority Date Filing Date
ES00102228T Expired - Lifetime ES2254055T3 (es) 1991-09-19 1992-09-18 Flavivirus quimericos y/o de crecimiento restringido.
ES98109234T Expired - Lifetime ES2153223T3 (es) 1991-09-19 1992-09-18 Flavivirus quimericos y/o flavivirus de crecimiento restringido.
ES92920708T Expired - Lifetime ES2140418T3 (es) 1991-09-19 1992-09-18 Flavivirus quimericos y/o flavivirus de crecimiento restringido.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES00102228T Expired - Lifetime ES2254055T3 (es) 1991-09-19 1992-09-18 Flavivirus quimericos y/o de crecimiento restringido.
ES98109234T Expired - Lifetime ES2153223T3 (es) 1991-09-19 1992-09-18 Flavivirus quimericos y/o flavivirus de crecimiento restringido.

Country Status (10)

Country Link
EP (4) EP1605047B1 (es)
JP (3) JP3531934B2 (es)
AT (4) ATE443143T1 (es)
AU (1) AU667836B2 (es)
CA (1) CA2116980C (es)
DE (4) DE69230316T2 (es)
DK (2) DK0604566T3 (es)
ES (3) ES2254055T3 (es)
GR (2) GR3032416T3 (es)
WO (1) WO1993006214A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
DE19521705C2 (de) 1995-06-14 1997-10-09 Immuno Ag Immunogenes Konstrukt, Verfahren zu dessen Herstellung und Verwendung als Vakzine
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
CA2282790C (en) * 1997-02-28 2011-04-19 St. Louis University Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
ATE314476T1 (de) * 1997-10-08 2006-01-15 Us Gov Health & Human Serv Chimärer impfstoff gegen das zeckenenzephalitis virus
US5968732A (en) * 1997-12-31 1999-10-19 Akzo Nobel, N.V. Isothermal transcription based assay for the detection and genotyping of dengue virus
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7417136B1 (en) 1998-06-04 2008-08-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6685948B1 (en) * 1998-09-02 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines
AU774045B2 (en) * 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
CA2941182A1 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
DK1441761T3 (da) * 2001-10-19 2007-08-27 Acambis Inc Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
CA2472468C (en) * 2002-01-10 2015-11-24 Alexander G. Pletnev Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
EP1572941A4 (en) 2002-02-26 2009-03-18 Maxygen Inc NEW FLAVIVIRUS ANTIGENES
AU2003290985B2 (en) 2002-11-15 2010-04-01 Acambis Inc. West nile virus vaccine
CN100557027C (zh) * 2003-03-31 2009-11-04 霍夫曼-拉罗奇有限公司 用于检测包括日本脑炎病毒血清群成员在内的某些黄病毒的组合物和方法
KR20070121853A (ko) 2003-03-31 2007-12-27 에프. 호프만-라 로슈 아게 일본 뇌염 바이러스 혈청군의 구성원을 포함하는, 특정플라비바이러스 검출용 조성물 및 방법
CN1299768C (zh) * 2004-08-13 2007-02-14 崔栋 人用二倍体细胞乙型脑炎纯化疫苗的制备方法
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
AU2005320001B2 (en) * 2004-12-24 2011-05-19 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
CN103031279B (zh) 2005-04-24 2015-11-18 赛诺菲巴斯德生物制药有限责任公司 重组黄病毒疫苗
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
BRPI0611581B1 (pt) * 2005-06-24 2021-08-03 Intervet International B.V. Flavivírus quimérico inativado, composição imunogênica, e, vacina
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US9211323B2 (en) 2009-06-01 2015-12-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
WO2011026139A1 (en) 2009-08-31 2011-03-03 Gen-Probe Incorporated Dengue virus assay
CA3177572C (en) 2013-03-15 2026-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
US11123420B2 (en) 2015-09-30 2021-09-21 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
US20200390877A1 (en) 2017-12-07 2020-12-17 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91304A0 (en) * 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus

Also Published As

Publication number Publication date
JP3531934B2 (ja) 2004-05-31
DE69231570D1 (de) 2000-12-21
DE69233566D1 (de) 2005-12-29
ATE310824T1 (de) 2005-12-15
DK0604566T3 (da) 2000-04-10
AU2691492A (en) 1993-04-27
EP0604566A4 (en) 1995-03-29
WO1993006214A1 (en) 1993-04-01
EP0604566B1 (en) 1999-11-17
JP2002325593A (ja) 2002-11-12
JP3681369B2 (ja) 2005-08-10
EP1605047A1 (en) 2005-12-14
DE69231570T2 (de) 2001-06-21
DE69230316T2 (de) 2000-07-13
DE69230316D1 (de) 1999-12-23
GR3035149T3 (en) 2001-04-30
EP1018556A1 (en) 2000-07-12
JP3681358B2 (ja) 2005-08-10
ATE186744T1 (de) 1999-12-15
DE69233566T2 (de) 2006-08-03
AU667836B2 (en) 1996-04-18
ATE197607T1 (de) 2000-12-15
CA2116980C (en) 2006-06-06
EP1018556B1 (en) 2005-11-23
EP0604566A1 (en) 1994-07-06
DE69233770D1 (de) 2009-10-29
EP0872553A1 (en) 1998-10-21
EP0872553B1 (en) 2000-11-15
GR3032416T3 (en) 2000-05-31
EP1605047B1 (en) 2009-09-16
DK0872553T3 (da) 2001-02-05
JPH06511150A (ja) 1994-12-15
ES2254055T3 (es) 2006-06-16
ES2153223T3 (es) 2001-02-16
CA2116980A1 (en) 1993-04-01
JP2003135085A (ja) 2003-05-13
ATE443143T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
ES2153223T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
DE60035778D1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
BG102712A (en) Mixture of recombinant vaccinia vectors as polyenv-vaccines against hiv
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
EE05138B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
AR003135A1 (es) Baculovirus recombinante, una vacuna que los contiene, y el uso del mismo para preparar una vacuna util para evitar o disminuir la enfermedad causada porvirus de inmunodeficiencia felina.
MX9202512A (es) Virus de avipox recombinante, cultivo de celulas infectadas por este virusy vacunas para las aves de corral derivadas de este virus.
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
BR0206112A (pt) Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
DE59908783D1 (de) Virus-vakzine
AR021406A1 (es) Un mutante del virus de la rabia recombinante, y una vacuna antirrabica con virus vivos atenuados
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
ES2191842T3 (es) Interleucina-8 como agente antiviral y antitumoral.
ATE453708T1 (de) Impfstoff gegen west nile virus
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
BR0002602A (pt) Vacina viva atenuada, uso de uma bactéria viva atenuada, e, processo para a preparação de uma vacina
AR024212A1 (es) Virus celo recombinante y adn de virus celo.
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
MY145463A (en) Flavivirus ns1 subunit vaccine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 604566

Country of ref document: ES